• 1
    Heffernan RT, Barret NL, Gallagher KM et al. Declining incidence of invasive Streptococcus pneumoniae infection among persons with AIDS in the era of highly active antiretroviral therapy, 1995–2000. J Infect Dis 2005; 191: 20382045.
  • 2
    Jordano Q, Falcó V, Almirante B et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38: 16231628.
  • 3
    Nuorti JP, Butler JC, Gelling L et al. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000; 132: 182190.
  • 4
    Grau I, Pallares R, Tubau F et al. Epidemiological changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165: 15331540.
  • 5
    Klugman KP, Madhi SA, Feldman CC. HIV and pneumococcal disease. Curr Opin Infect Dis 2007; 20: 1115.
  • 6
    Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173: 857862.
  • 7
    Dworkin MS, Ward JW, Hanson DL, Lones JL, Kaplan JE; the Adult and Adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: risk factors and impact of vaccination. Clin Infect Dis 2001; 32: 794800.
  • 8
    Campo RE, Campo CE, Garnet P et al. Differences in presentation and outcome of invasive pneumococcal disease among patients with and without HIV infection in the pre-HAART era. AIDS patients care STDS 2005; 19: 141149.
  • 9
    Kyaw MH, Rose CE, Fry AM et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005; 192: 377386.
  • 10
    Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990–2003. AIDS 2006; 20: 437444.
  • 11
    Lopez-Palomo C, Martin-Zamorano M, Benitez E et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of pneumococcal vaccination. J Med Virol 2004; 72: 517524.
  • 12
    Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004; 22: 20062012.
  • 13
    Peñaranda M, Falcó V, Payeras A et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case–control study. Clin Infect Dis 2007; 45: e82e87.
  • 14
    Guerrero M, Krueger S, Saitho A et al. Pneumonia in HIV-infected patients: a case-control study of factors involved in risk and prevention. AIDS 1999; 13: 19711975.
  • 15
    Breiman RF, Keller DW, Phelan MA et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000; 160: 26332638.
  • 16
    French N, Nakiyingi J, Carpenter LM et al. 23-valent polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355: 21062111.
  • 17
    Watera C, Nakiyingi J, Miiro G et al. 23-valent polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004; 18: 12101213.
  • 18
    Lindenburg CE, Langendam MW, Benthem BH, Miedema F, Coutinho RA. No evidence that vaccination with a polysaccharide pneumococcal vaccine protects drug users against all-cause pneumonia. AIDS 2001; 15: 13151317.
  • 19
    Mandell LA, Wunderink RG, Anzueto A et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27S72.
  • 20
    Recommendations of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the HIV Medicine Association of the Infectious Diseases Society of America (HIVMA/IDSA). Available at:
  • 21
    Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007; 167: 19381943.
  • 22
    Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006; 42: 10931101.
  • 23
    Mykietiuk A, Carratalá J, Dominguez A et al. Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur J Microbiol Infect Dis 2006; 25: 457462.
  • 24
    Klugman KP, Madhi SA, Huebner RE et al, for the Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV Infection. N Engl J Med 2003; 349: 13411348.
  • 25
    Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marie TJ. Statins and outcomes in patients admitted to hospital with community-acquired pneumonia: population-based prospective cohort study. BMJ 2006; 333: 9991001.
  • 26
    Robinson KA, Baughman W, Rothrock G et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998. JAMA 2001; 285: 17291735.
  • 27
    Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995; 332: 12801284.
  • 28
    Fedson DS, Musher DM. Pneumococcal polysaccharide vaccine. In: PlotkinSA, OrensteinWA. eds. Vaccines, 4th edn. Philadelphia, PA: WB Saunders, 2004.
  • 29
    Rodriguez-Barradas MC, Alexandraki I, Nazir T et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003; 37: 438447.
  • 30
    Tasker SA, Wallace MR, Rubins JB, Paxton WB, O'Brien J, Janoff EN. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34: 813821.
  • 31
    McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 2000; 181: 757760.